Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

such as the 5-HT 1A receptor, are considered to mediate the ability of antipsychotic drugs to enhance cognition. On the other hand, treatment with some atypical agents, such as risperidone ...

Significant weight gain is a common side effect of many psychiatric medications. Fortunately, there are options for those who ...

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a ...

But expanding Cobenfy’s approval to use on top of non-risperidone antipsychotics may require ... designed to target and block muscarinic receptors in the brain. The drug, formulated as a twice ...

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

By Sriparna Roy (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Receptor pharmacology is the study of the interactions of receptors with drugs/pharmaceuticals and other xenobiotics. A basic tenet of receptor pharmacology is that a drug’s effect is directly ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

Doctors and patients hope it can provide an alternative to generic antipsychotics, which can often curb key symptoms but come with significant side effects. In the new trial, Bristol tested to ...

While sprinkling cinnamon on food is likely safe, concentrated supplements might pose risks, especially for people taking ...